Scarica l'app Stockscreener
1.025
0.49%
-0.005
Dopo l'orario di chiusura:
1.00
-0.025
-2.44%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.03
Aprire:
$1.04
Volume 24 ore:
93,070
Relative Volume:
0.16
Capitalizzazione di mercato:
$11.91M
Reddito:
-
Utile/perdita netta:
$-10.93M
Rapporto P/E:
-0.7129
EPS:
-1.4378
Flusso di cassa netto:
$-10.72M
1 W Prestazione:
-1.44%
1M Prestazione:
+0.00%
6M Prestazione:
+1.49%
1 anno Prestazione:
-56.93%
Intervallo 1D:
$1.00
$1.05
Intervallo di 1 settimana:
$0.9506
$1.0699
Portata 52W:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.025 | 12.20M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Cash Flow - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.050| - TradingKey
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Market Sentiment - Benzinga España
Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO - TradingView
PHIO|Phio Pharmaceuticals Corp|Price:1.040| - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.055|Chg%:+0.015 - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.13Sector ETF Flow - dars.gov.et
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation - Bitget
Phio Pharmaceuticals to present its INTASYL siR... - Pluang
Phio Pharmaceuticals CEO Robert Bitterman to Showcase INTASYL Gene Silencing Platform at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals to Showcase INTASYL siRNA Platform and PH-762 Skin Cancer Therapy at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals Appoints Dr. R. Todd Plott to Board of Directors, Strengthening Expertise in Dermatologic Research and Commercialization – Minichart - Minichart
Phio Pharmaceuticals appoints dermatologist to board By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints dermatologist to board - Investing.com
Phio Pharmaceuticals adds dermatology expert to board - TipRanks
Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee - TradingView
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors - The Globe and Mail
Phio Pharmaceuticals Strengthens Board with Dermatology Expert Dr. R. Todd Plott Amid PH-762 Clinical Progress - Kalkine Media
Phio Pharmaceuticals (PHIO) Rises 3% to $1.03, Tests Key Resistance at $1.08TPO Profile - dars.gov.et
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision - EIN Presswire
Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones - Yahoo Finance
Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan - Investing.com Canada
Phio's INTASYL patent portfolio consists of 54 issued patents - Stock Titan
Phio Pharmaceuticals Expands Global Patent Portfolio with Multiple Approvals in U.S., Canada, and Japan for INTASYL siRNA Technology - Kalkine Media
Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to book forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Slips 1.92% as Stock Tests Key Support at $0.97Sign of Strength - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentAnalyst Earnings Estimate - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEPS Estimate Trend - dars.gov.et
PHIO PE Ratio & Valuation, Is PHIO Overvalued - Intellectia AI
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock - Investing.com
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com - Investing.com Nigeria
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
Form 4 Phio Pharmaceuticals Corp For: 29 June By Investing.com - Investing.com South Africa
PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact - TradingView
PHIO: PH-762 achieved 85% response with no serious adverse events; next trial planned for early next year - TradingView
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 - TMX Newsfile
PHIO PHARMACEUTICALS CORP (PHIO) Stock Chart - ChartMill
Phio Pharmaceuticals (PHIO) Second Annual Centri Capital Conference Summary - Quartr
Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary - Quartr
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - The National Law Review
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phio Pharmaceuticals Corp Azioni (PHIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 31 '25 |
Buy |
1.03 |
5,000 |
5,150 |
291,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):